Earnings Call Transcripts

Access detailed transcripts and key takeaways from company earnings calls

All Earnings Calls

SKLZ April 1, 2026

Skillz Inc. Q4 2025 Earnings Call - RZR drives profitability, revenue stabilizes, but developer concentration and near-term debt maturity loom

Skillz closed 2025 with sequential revenue growth and clear progress on cost discipline, led by a resurging ad tech unit, RZR. Q4 revenue climbed to $30 million, full-year revenue reached $105 million...

  • Q4 2025 GAAP revenue was $30 million, up 11% sequentially and up 67% year over year from $18 million in Q4 2024.
  • Full-year 2025 GAAP revenue was $105 million, a 13% increase from $93 million in 2024.
  • Q4 2025 Adjusted EBITDA loss improved to $10 million, versus a $12 million loss in Q3 2025 and a $17 million loss in Q4 2024.
  • +12 more takeaways
CSAI April 1, 2026

Cloudastructure Q4 2025 Earnings Call - Revenue up 271% as ARR tops $2M and multifamily rollouts drive scale

Cloudastructure closed 2025 with a leap in top-line traction, reporting $5.1 million in revenue, a 271% year-over-year jump driven by larger multi-site deals and expansion in multifamily property mana...

  • Full-year 2025 revenue was $5.1 million, up 271% year-over-year.
  • Year-over-year total contract value rose 342%, signaling larger multi-site deployments and deeper customer commitments.
  • Management reports year-ending ARR above $2.0 million, driven by cloud video surveillance and remote guarding subscriptions.
  • +14 more takeaways
NG April 1, 2026

NovaGold Resources Inc. Q1 2026 Earnings Call - Donlin BFS Underway, 12-18 Month Clock Started

NovaGold used the quarter to move Donlin from promise to project. Management formally awarded the bankable feasibility study to Fluor and assembled specialty engineering partners, saying the 12 to 18 ...

  • Bankable feasibility study (BFS) for Donlin Gold has been awarded to Fluor and the company says the 12 to 18 month clock has effectively started.
  • NovaGold now reflects a 60% interest in Donlin Gold in its results, increasing its direct project exposure and funding responsibility.
  • Treasury sits at $392.5 million after a private placement, and management intends to use proceeds to fund Donlin BFS work, prepay the Barrick promissory note, and for general corporate purposes.
  • +11 more takeaways
PED April 1, 2026

PEDEVCO Q4 2025 Earnings Call - Merger Scales a Rocky-Focused Platform, now Selling a Story of Cost Cuts and Optionality

PEDEVCO used the Oct 31, 2025 Juniper merger to leap from a micro-cap producer to a scaled, Rocky-focused E&P with meaningful development optionality. Reported Q4 numbers include only partial contribu...

  • Merger closed Oct 31, 2025 with Juniper portfolio, creating a Rocky-focused platform and retroactive 1-for-20 reverse split effective Mar 13, 2026.
  • Scale jump: production went from ~1,500 BOE per day pre-merger to a combined Q4 average of over 5,300 BOE per day, with Q4 total production reported at 483,159 BOE.
  • Proved reserves nearly doubled to 32.1 million BOE, which management values at roughly $27 per share on a post-split basis.
  • +16 more takeaways
LW April 1, 2026

Lamb Weston Q3 Fiscal 2026 Earnings Call - North America execution masks international pain, cost cuts on track

Lamb Weston reported a mixed quarter. North America drove the beat with customer wins, 12% volume growth and stronger retention, allowing management to tighten guidance and raise the net sales and EBI...

  • Company tightened fiscal 2026 guidance, raising the net sales midpoint and narrowing the range; new net sales guidance $6.45B to $6.55B, adjusted EBITDA guidance $1.08B to $1.14B.
  • Overall Q3 net sales grew 3% including a $47M FX benefit, while constant currency net sales were essentially flat year over year.
  • Total company volume was up 7% in Q3, driven by North America where volume rose 12% and net sales in the segment rose 5%.
  • +13 more takeaways
BTBT April 1, 2026

Bit Digital Q4 and Full Year 2025 Earnings Call - Repositioned as SAC focused on Ethereum staking and WhiteFiber AI infrastructure

Bit Digital declared a strategic pivot in 2025, repositioning itself as a Strategic Asset Company built around an Ethereum treasury and staking platform, plus a majority stake in WhiteFiber for AI inf...

  • Company repositioned as a Strategic Asset Company centered on Ethereum and AI infrastructure, emphasizing ETH per share and long-term compounding.
  • Management began exiting Bitcoin mining, active hash rate was approximately 1.5 exahash at year-end, and no growth or replacement capital will be allocated to mining.
  • WhiteFiber is consolidated on Bit Digital’s statements, management holds a majority (about 70%) stake, and they do not intend to monetize that position in 2026.
  • +13 more takeaways
PVH April 1, 2026

PVH Corp Q4 2025 Earnings Call - Margin Resilience and D2C Momentum Despite Rising Tariffs

PVH closed 2025 by beating Q4 guidance on revenue, operating profit and EPS, while signaling a cautious but constructive start to 2026. The company delivered sequential gross margin improvement across...

  • Q4 results beat guidance: reported revenue up mid-single digits, flat in constant currency, with Q4 non-GAAP operating margin of 10% and EPS up 17% year over year to $3.82.
  • Full year 2025 delivered reported revenue up 3%, non-GAAP operating margin of 8.8%, and EPS of $11.40, ahead of guidance despite tariff disruption.
  • Tariff headwind is material and accelerating, management assumes a 15% U.S. tariff effective Feb 24, 2026, and projects approximately $195 million gross tariff cost to EBIT, or roughly $3.30 per share, in 2026.
  • +12 more takeaways
TLRY April 1, 2026

Tilray Brands Q3 FY2026 Earnings Call - Record quarter as international cannabis surges and BrewDog deal lifts run-rate toward $1.2B

Tilray reported a record Q3 with net revenue of $206.7 million, driven by a breakout quarter in international cannabis and continued progress across distribution and wellness. Management leaned into t...

  • Record Q3 net revenue of $206.7 million, up 11% year-over-year, driven by multi-segment growth across cannabis, distribution, beverage and wellness.
  • Gross profit rose to $55 million, a 6% increase year-over-year; gross margin modestly declined to 27% from 28% due to mix and input cost pressures.
  • Tilray ended the quarter with $264.8 million of cash, restricted cash and marketable securities and approximately $3.5 million net cash, an improvement of $40.2 million from a year ago when the company was net debt.
  • +15 more takeaways
CALM April 1, 2026

Cal-Maine Foods Q3 FY2026 Earnings Call - Specialty and Prepared Foods Now Drive the Business as Commodity Prices Collapse

Cal-Maine reported a crushing year-over-year revenue and profit reset as wholesale egg prices normalized from last year’s HPAI shock, but the company’s deliberate portfolio shift showed up loud and cl...

  • Net sales plunged 53% year-over-year to $667 million, reflecting a sharp unwind from last year’s HPAI-driven price spikes.
  • Conventional egg sales collapsed 72.1% year-over-year to $283.2 million, driven primarily by a 70.1% drop in selling prices and a 6.7% decline in volumes.
  • Specialty egg sales were down 12.1% to $289.1 million, but volumes rose 5.8% and specialty now represents 50.5% of shell egg sales in Q3, vs 24.4% a year ago.
  • +12 more takeaways
VNRX April 1, 2026

VolitionRx Limited Full Fiscal Year 2025 Earnings Call - Clinical commercialization accelerates as NETs and Nu.Q Cancer move into real-world use and Capture-Seq shows >99% pure ctDNA

VolitionRx says 2025 was a pivot year, shifting from R&D into commercialization with tangible, near-term clinical deployments. The company reported its first CE Mark Nu.Q NETs revenues, a first order ...

  • Nu.Q NETs included as sole biomarker in DETECSEPS, a French government-backed interventional program worth about $7.3 million, marking imminent real-world clinical use for early sepsis detection.
  • Volition received its first order of Nu.Q Cancer assays from Hospices Civils de Lyon for clinical certification ahead of routine clinical use; company targeting reimbursement submission in France and routine use by Q4 2026.
  • First commercial revenue recognized from the CE Mark Nu.Q NETs automated assay during 2025, and 12 hospital networks are currently evaluating the assay across 15 clinical use cases.
  • +14 more takeaways